23ANDME

The idea started in a living room in 2006. Anne Wojcicki and Linda Avey had a simple premise: DNA testing was stuck in hospitals and research labs, accessible only to doctors and scientists.

What if regular people could just know what was in their own genome? Wojcicki had spent years in healthcare investing.

Avey came from genomics research. Together they believed that democratizing access to genetic information would unlock something big — for consumers, for science, and eventually for drug discovery.

They named the company after the 23 pairs of chromosomes in a human cell. The logo was a double helix.

The pitch was: send us your spit, we'll send you your story. They launched the consumer product in 2007 at $999 per kit.

It was a novelty at first — journalists wrote about it, early adopters bought it as a conversation starter, and the phrase 'direct-to-consumer genetic testing' entered the vocabulary.

The early years were messy. The FDA came knocking in 2013 and ordered 23andMe to stop selling health-related genetic reports because they hadn't gone through medical device approval.

The company complied, stripped out the health features, and spent two years navigating the regulatory maze. When they came back with FDA-approved health reports in 2015, they came back stronger.

The price had dropped to $199. The database was growing.

And the real business — the one hiding behind the consumer product — was just beginning to take shape.

On the surface, 23andMe sells spit kits. You pay $99 to $229, mail in a tube of saliva, and get back a report telling you your ancestry breakdown, whether you carry genes for certain conditions, and fun facts like whether you're likely to have wet or dry earwax.

That's the consumer business.

But the real play was always the database. Every person who bought a kit — and opted into research, which most people did — added their genetic data to a growing repository.

By 2023, that repository held data from roughly 15 million people. That is an extraordinary scientific asset.

Drug companies trying to understand why some people get Alzheimer's and others don't, or why certain treatments work on some patients and fail on others, would pay serious money for access to a dataset that large and that clean.

So 23andMe built a pharma research business. They partnered with GlaxoSmithKline in 2018 in a deal worth $300 million.

GSK got access to the database to accelerate drug discovery. 23andMe got cash and credibility.

The theory was that the consumer product would keep growing the database, the database would keep attracting pharma partners, and the research business would eventually generate the kind of recurring, high-margin revenue that would justify a multibillion-dollar valuation.

The theory was right. The execution — and the timing — was the problem.

The core product is the DNA testing kit — a small tube you spit into, seal up, and mail back to the lab. A few weeks later you get access to an online report.

The ancestry breakdown is the flagship feature: it tells you the percentage of your DNA that traces back to different regions around the world, from broad categories like 'Sub-Saharan Africa' down to more granular results like 'French and German' or 'Scandinavian'. The database is big enough now that the regional resolution is actually impressive.

The health reports are where it gets more medically interesting. 23andMe offers FDA-cleared reports on genetic health risks — including variants associated with BRCA1 and BRCA2 (linked to breast and ovarian cancer), APOE variants linked to late-onset Alzheimer's, and carrier status for conditions like cystic fibrosis and sickle cell anemia.

These aren't diagnostic tools — they tell you about genetic risk, not certainty — but for people who'd never had access to genetic screening, they were genuinely eye-opening.

The DNA Relatives feature connected users with genetic relatives in the database. This became one of the most emotionally powerful features on the platform — people discovered half-siblings they didn't know existed, reconnected with estranged family branches, and in some cases uncovered secrets their parents had kept for decades.

It was also the feature that made the data breach so alarming.

Total Health was their subscription play — a more comprehensive health monitoring product launched in 2023, combining genetic insights with ongoing lab testing and health coaching. It was priced at around $2,000 per year.

It was a smart pivot. It came too late.

The growth hack was pricing. When 23andMe launched, genetic testing cost thousands of dollars in clinical settings.

They started at $999, which felt cheap by comparison. Then they kept cutting.

$499. $299.

$199. $99 during Black Friday sales.

Each price drop unlocked a new wave of buyers and a new cohort of data donors. The kit became a popular gift — something you bought for a curious parent or a spouse who'd always wondered about their heritage.

Holiday seasons were their Super Bowl.

The celebrity angle helped too. Oprah mentioned it.

Magazines ran 'I tried 23andMe' stories. The narrative of self-discovery — finding out you were 4% Ashkenazi Jewish, connecting with a half-sibling you never knew existed, learning you carry a BRCA gene variant — gave people an emotional reason to buy that no other health product had ever quite managed.

They also leaned hard into the ancestry angle, which turned out to be a massive demand driver. People who had zero interest in their health markers would still fork out $99 to find out where their great-great-grandparents came from.

The ancestry product brought in millions of buyers who then sat in the database as potential research participants. Growth was real.

The problem was that growth in kit sales doesn't automatically mean growth in revenue — and the research partnership model never scaled the way they needed it to.

Three things nearly killed 23andMe — and eventually two of them succeeded.

First was the FDA. Getting shut down in 2013 before you've really launched is a brutal blow.

Spending two years rebuilding regulatory relationships while competitors chip away at your market is demoralizing and expensive. They survived it, but it cost them momentum they never fully recovered.

Second was the data breach. In October 2023, hackers got into customer accounts — mostly through credential stuffing, using passwords people had reused from other breached sites — and accessed the genetic data of roughly 6.9 million customers.

That is nearly half their entire user base. The data included health information, ancestry reports, family connections.

It was a catastrophic breach of trust for a company whose entire value proposition was 'you can trust us with the most personal data imaginable.' Lawsuits followed immediately. The regulatory scrutiny intensified.

And the timing couldn't have been worse — they were already losing money fast.

Third was the business model itself. 23andMe never cracked recurring revenue.

You buy one kit. Maybe two.

But you don't come back every month. The subscription product they launched — a membership service called Total Health — was an attempt to fix that, but uptake was too slow to matter.

The pharma partnership pipeline also underdelivered. GlaxoSmithKline wound down their collaboration in 2023 after the initial term expired.

Without a second major deal to replace it, the revenue side of the equation started falling apart. By early 2024, the company had laid off 40% of its workforce.

By 2025, it had filed for Chapter 11.

23andMe's earliest institutional backing came from Genentech, which invested in 2007 — a significant signal from a major biotech player that the science was credible. Google also came in early, with Sergey Brin personally investing (he was married to Anne Wojcicki at the time, which made for interesting board dynamics and an awkward divorce).

That Google connection gave 23andMe enormous credibility in Silicon Valley and opened doors to follow-on fundraising.

New Enterprise Associates, Johnson and Johnson Development Corporation, and Casdin Capital were among the investors across various rounds as the company scaled. The biggest vote of confidence came in 2021 when 23andMe went public via a SPAC merger with VG Acquisition Corp — a blank-check company backed by Richard Branson's Virgin Group.

The deal gave 23andMe a valuation of roughly $3.5 billion at close. The SPAC structure was, in hindsight, a sign of the times: 2021 was the peak of speculative growth-at-any-cost investing, and 23andMe was exactly the kind of story that SPAC investors loved — a company with a huge addressable market, a massive moat, and a charismatic founder with a famous ex-husband.

The stock peaked above $17 shortly after listing. By 2024 it was trading under $0.50.

The company's market cap had collapsed from a post-SPAC high of around $6 billion to less than $100 million. Shareholders had been nearly wiped out.

The board — which had rejected Wojcicki's multiple attempts to take the company private and rescue it — resigned en masse in September 2024. The bankruptcy filing followed.